Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,612.82
(
-0.18%
)
US TECH 100
23,734.40
(
-0.26%
)
Dow Jones
46,114.09
(
-0.24%
)
Brent Oil
103.40
(
-2.98%
)
Bitcoin
70,446.84
(
-1.12%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: masterlongevity post# 55065

Tuesday, 11/20/2007 11:49:56 AM

Tuesday, November 20, 2007 11:49:56 AM

Post# of 257259
>i can't see an advantage that this [GenMab/GSK] product would have over 2H7, the 2nd gen fully human Rituxan. And it is about 1.5 years behind it in development.<

Between cancer and autoimmune diseases, the market for follow-ons to Rituxan is so big that there are multiple contenders. When the main CD20/Rituxan patent expires in 2014, GTCB hopes to come in with an FoB being co-developed with LFB of France.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now